Dr Reddy's Laboratories through its wholly owned subsidiary Promius Pharma Tuesday announced sale and assignment of the US rights for its marketed dermatology brands to Encore Dermatology.Promius Pharma, LLC, announced the sale of its rights for SERNIVO spray, 0.05 per cent and assignment of its rights to market and distribute, PROMISES topical cream and TRIANEX 0.05 per cent (Triamcinolone Acetonide ointment, USP) in the United States, to Encore Dermatology.
Promius Pharma is all in for skin for its latest campaign. The digital and social media push gathers multiple skin conditions under the banner “My Skin Matters” to promote positivity for people living with conditions such as eczema, psoriasis and acne.
Sernivo®(Betamethasone Dipropionate): Promius Pharma v. Taro Pharmaceuticals
Sernivo®(Betamethasone Dipropionate): Promius Pharma v. Perrigo Uk Finco
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and its subsidiary, Promius Pharma, LLC today announced the filing of New Drug Application (NDA) for its migraine candidate DFN-02 with the U.S. Food and Drug Administration (USFDA).
Promius Pharma`s Sernivo approved in US as topical steroid